Glucagon-like peptide-1 (GLP-1) circulates at low levels and acts as an incretin hormone, potentiating glucose-dependent insulin secretion from islet β cells. GLP-1 also modulates gastric emptying and engages neural circuits in the portal region and CNS that contribute to GLP-1 receptor–dependent (GLP-1R–dependent) regulation of glucose homeostasis. To elucidate the importance of pancreatic GLP-1R signaling for glucose homeostasis, we generated transgenic mice that expressed the human GLP-1R in islets and pancreatic ductal cells (Pdx1-hGLP1R:Glp1r+/− mice). Transgene expression restored GLP-1R–dependent stimulation of cAMP and Akt phosphorylation in isolated islets, conferred GLP-1R–dependent stimulation of β cell proliferation, and was sufficient for restoration of GLP-1–stimulated insulin secretion in perfused islets. Systemic GLP-1R activation with the GLP-1R agonist exendin-4 had no effect on food intake, hindbrain c-fos expression, or gastric emptying but improved glucose tolerance and stimulated insulin secretion in Pdx1-hGLP1R:Glp1r+/− mice. i.c.v. GLP-1R blockade with the antagonist exendin (9–39) impaired glucose tolerance in WT mice but had no effect in Pdx1-hGLP1R:Glp1r+/− mice. Nevertheless, transgenic expression of the pancreatic GLP-1R was sufficient to normalize both oral and i.p. glucose tolerance in Glp1r+/− mice. These findings illustrate that low levels of endogenous GLP-1 secreted from gut endocrine cells are capable of augmenting glucoregulatory activity via pancreatic GLP-1Rs independent of communication with neural pathways.

Introduction

Multiple tissues contribute to the maintenance of blood glucose levels after nutrient ingestion, with liver and muscle responsible for disposal of the majority of excess glucose in the postprandial state (1). In these tissues, glucose can either be used as a fuel for metabolism or stored in the form of glycogen for later use. Excess nutrients are also stored in adipose tissue. Insulin secreted from pancreatic β cells in response to nutrient ingestion regulates many of these processes. However, the pancreas is only one of many sites important for nutrient sensing and communication of metabolic signals regulating energy assimilation and storage (2).

Our understanding of adipose tissue has evolved from a passive site of fuel storage to a metabolically active tissue secreting adipokines, such as leptin, adiponectin, and resistin, that in turn regulate energy homeostasis (3, 4). In addition to sensing hormonal signals from peripheral tissues, the brain also senses and responds to nutrients directly and receives signals from afferent nerves reflecting peripheral inputs into glucose metabolism (5, 6). An important source of these afferent inputs is the intestine, an organ originating signals arising from enteral nutrients within minutes of food ingestion (7, 8) via an extensive neural network. The gut also releases multiple hormones (9) that in turn relay information via endocrine and neural circuits to the brain, pancreas, and other tissues controlling nutrient assimilation.

There is considerable interest in understanding how gut-derived signals communicate with the β cell to promote insulin secretion. Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are released from enteroendocrine cells of the intestine after food ingestion and stimulate insulin secretion in a glucose-dependent manner (10). However, due to the rapid cleavage of these peptide hormones by dipeptidyl peptidase 4, only a small percentage of the total GIP or GLP-1 secreted by the intestine actually reaches β cells in active form, rendering uncertain the mechanisms underlying the classical incretin concept (11, 12).

GLP-1 also exerts inhibitory actions on food intake and gastric emptying, involving activation of neurons within the hypothalamus (13–15). Reduced feeding activity can be seen after either i.c.v. or peripheral administration of GLP-1 receptor (GLP-1R) agonists, and CNS GLP-1R blockade increases food intake (16, 17), suggesting that even low basal levels of GLP-1R signaling control nutrient ingestion. Intriguingly, peripheral administration of high molecular weight GLP-1R agonists also reduces food intake (14, 18) and promotes weight loss (19), implying that signals originating from peripheral GLP-1R activation can be relayed to the brain.

Accumulating evidence suggests that activation of extrapancreatic GLP-1Rs represents an important mechanism underlying actions of GLP-1 on glucose metabolism (2, 20). The hepatoporal region is exposed to relatively higher levels of active GLP-1, and signals arising from the hepatoporal GLP-1R facilitate glucose clearance independent of changes in insulin secretion (21, 22). Moreover,
GLP-1 is also produced in brain stem and hypothalamic neurons (23–25), and augmentation or attenuation of central GLP-1 signaling can exert profound effects on peripheral glucose metabolism (26, 27). Furthermore, intraportal but not systemic administration of a GLP-1R antagonist or ganglionic blockade impairs GLP-1R–dependent control of glucose clearance (28, 29). Taken together, these findings challenge conventional concepts that GLP-1 acts predominantly on islet β cells to control glucose homeostasis (20).

To elucidate the importance of islet GLP-1Rs for glucoregulation, we used a transgenic rescue strategy to selectively restore human GLP-1R expression in pancreatic ductal and β cells of Glp1r–/– mice. Islets isolated from Glp1r–/– mice that expressed the human GLP-1R in islets and pancreatic ductal cells (Pdx1-hGLP1R:Glp1r–/– mice) displayed functional coupling of GLP-1R agonism to the stimulation of insulin secretion. Pdx1-hGLP1R:Glp1r–/– mice exhibited restoration of the glucoregulatory, proliferative, and insulin stimulatory effects of the GLP-1R agonist exendin-4 (Ex-4) in vivo. Furthermore, Pdx1-hGLP1R:Glp1r–/– mice displayed improved glucose tolerance compared with that of Glp1r–/– mice. Hence, selective restoration of the GLP-1R in the murine pancreas reveals the essential physiological role of the islet GLP-1R in the regulation of β cell function and glucose homeostasis.

**Results**

Pancreatic GLP-1R expression in Pdx1-hGLP1R:Glp1r–/– mice. A 4.6-kb genomic sequence containing the S’ promoter region of the mouse pancreatic and duodenal homeobox 1 (Pdx1) gene (30) was used to direct expression of the human GLP-1R cDNA (Pdx1-hGLP1R) in transgenic mice (Figure 1A). To selectively restore GLP-1R expression in pancreatic ductal and β cells, Glp1r–/– mice were crossed with Pdx1-hGLP1R transgenic mice, and the resulting Pdx1-hGLP1R:Glp1r–/– mice were crossed to generate Pdx1-hGLP1R:Glp1r–/– mice. WT littermates (Glp1r–/– mice) and Pdx1-hGLP1R and Glp1r–/– mice were used as controls (Figure 1B).

Real-time PCR demonstrated expression of the transgene in Pdx1-hGLP1R:Glp1r–/– mice predominantly in pancreatic islets.
Moreover, the relative levels of human GLP1R mRNA transcripts in Pdx1-hGLP1R:Glp1r−/− mouse islets were similar to levels of endogenous murine Glp1r mRNA transcripts in islets from WT control mice (Figure 1, D and E). Immunohistochemistry localized the human GLP-1R (hGLP-1R) protein to pancreatic islets and occasional ductal cells in histological sections from Pdx1-hGLP1R:Glp1r−/− pancreata (Figure 1C). The expression of the hGLP1R transgene did not significantly alter the basal levels of mRNA transcripts encoding GLP-1–regulated genes important for glucose homeostasis (Pdx1, Ins2, Gipr, Glut2, Gck, Kir6.2, Akt1) in islets from Pdx1-hGLP1R:Glp1r−/− mice (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI42497DS1). Two independent lines of transgenic Pdx1-hGLP1R:Glp1r−/− mice were generated and analyzed. Both lines showed similar patterns of transgene expression and metabolic (glucose tolerance, insulin secretion, and food intake) responses to GLP-1R agonists (data not shown); therefore, all of the results presented herein are derived from analysis of a single transgenic mouse line.

Consistent with these findings, Ex-4 promoted Akt phosphorylation in Pdx1-hGLP1R:Glp1r−/− transgenic islets (Figure 2B and C). Hence, the human GLP-1R is functional and engages downstream signal transduction pathways in Pdx1-hGLP1R:Glp1r−/− islets.

We next examined whether restoration of GLP-1R signaling in Pdx1-hGLP1R:Glp1r−/− islets was coupled to GLP-1–stimulated enhancement of insulin secretion. Perifusion of isolated islets ex vivo with 16.7 mM glucose induced insulin secretion to similar levels as those from islets of all genotypes (Figure 3, A and B). When GLP-1 was added to the 16.7 mM glucose perifusion media, both WT and Pdx1-hGLP1R transgenic islets responded with a sustained increase in insulin secretion (Figure 3C). In comparison, islets from Glp1r−/− mice did not increase insulin secretion in response to GLP-1 (Figure 3, C and D). Expression of the hGLP1R transgene in Pdx1-hGLP1R:Glp1r−/− islets restored the direct potentiating effect of GLP-1 on glucose-stimulated insulin secretion (Figure 3, C and D).

Normalization of glucose tolerance in Pdx1-hGLP1R:Glp1r−/− mice. The observation that Glp1r−/− mice exhibit impaired glucose tolerance illustrates the importance of basal GLP-1R signaling for glucose homeostasis (32). We examined whether restoration of islet hGLP1R expression is sufficient for normalization of glucose tolerance in Glp1r−/− mice. Consistent with our original observations (33), the response to oral glucose was impaired in both male (Figure 4, A and C) and female (Figure 4, B and D) Glp1r−/− mice, without detectable changes in plasma insulin levels (Figure 4, E and F), as demonstrated previously (34–36). Plasma GLP-1 levels
were increased in Glp1r−/− mice, but no changes in GIP or glucagon levels were detected across genotypes (Supplemental Figure 2, A–C). Remarkably, glucose tolerance was normalized in Pdx1-hGLP1R:Glp1r−/− mice (Figure 4, C and D). These results illustrate that basal β cell GLP-1R expression is important for maintaining glucose tolerance, independent of any potential compensatory adaptation arising from changes in levels of related glucoregulatory hormones such as glucagon or GIP.

**Pharmacological activation of the pancreatic GLP-1R improves glucose tolerance.** To determine the importance of the islet GLP-1R for the acute glucoregulatory response to exogenous GLP-1R agonists, we assessed glucose tolerance in the presence or absence of the GLP-1R agonist Ex-4. To avoid potential confounding influences of related endogenous incretin-like signals generated in response to enteral glucose (34), we first carried out i.p. glucose tolerance tests (IGTTs). Ex-4 markedly reduced blood glucose and increased plasma insulin levels after i.p. glucose administration in WT mice (Figure 5A) and in Pdx1-hGLP1R transgenic mice (Figure 5B). In contrast, Ex-4 had no effect on i.p. glucose tolerance or insulin levels in Glp1r−/− mice (Figure 5C). A robust glucoregulatory and insulinotropic response to Ex-4 was restored in Pdx1-hGLP1R:Glp1r−/− mice, with the magnitude of the responses comparable to those observed in WT mice (compare Figure 5D with Figure 5A). Analogous results were seen after Ex-4 administration, in conjunction with oral glucose administration (Supplemental Figure 3). Hence, selective GLP-1R activation in pancreatic islets is sufficient to convey a robust pharmacodynamic response coupled to improvements in glucose homeostasis.

**Absence of extrapancreatic metabolic effects of Ex-4 in Pdx1-hGLP1R:Glp1r−/− mice.** As GLP-1R activation may also regulate glucose homeostasis through actions on the gastrointestinal tract and CNS (20), extrapancreatic GLP-1R actions might confound interpretation of data obtained in Pdx1-hGLP1R:Glp1r−/− mice. Accordingly, we assessed whether Ex-4 inhibited gastric emptying in mice of different genotypes. Ex-4 reduced the rate of appearance of acetaminophen in plasma from WT and Pdx1-hGLP1R transgenic mice (Figure 6, A and B) but had no effect on gastric emptying in Glp1r−/− mice (Figure 6C) or in Pdx1-hGLP1R:Glp1r−/− mice.
Similarly, Ex-4 significantly reduced food intake in WT (Figure 7A) and Pdx1-hGLP1R transgenic mice (Figure 7B) but not in Glp1r−/− mice (Figure 7C) or in Pdx1-hGLP1R:Glp1r−/− mice (Figure 7D). These findings provide evidence for disruption of classical GLP-1R-regulated circuits in the nervous system of Pdx1-hGLP1R:Glp1r−/− mice.

Peripheral or centrally administered GLP-1R agonists also promote neuronal activation, detected by analysis of c-fos expression in the hindbrain and hypothalamus (15, 37, 38). Hence, we assessed whether Ex-4 administered via i.p. injection induced c-fos expression in the brains of Pdx1-hGLP1R:Glp1r−/− mice. Ex-4 increased levels of c-fos mRNA transcripts in the area postrema (AP) and nucleus of the solitary tract (NTS) areas of the hindbrain (Figure 8, A and B) in WT and Pdx1-hGLP1R mice but not in Glp1r−/− or Pdx1-hGLP1R:Glp1r−/− mice (Figure 8, A and B). The number of c-Fos-positive neurons in the AP and NTS was robustly increased by Ex-4 treatment in WT and Pdx1-hGLP1R mice (Figure 8, C–E); however, these effects were completely absent in Glp1r−/− mice and substantially diminished or absent in Pdx1-hGLP1R:Glp1r−/− mice (Figure 8, C–E). Taken together, these findings further illustrate disruption of central GLP-1R signaling in Pdx1-hGLP1R:Glp1r−/− mice.

The extrapancreatic effects of the GLP-1R antagonist exendin(9–39) are absent in Pdx1-hGLP1R:Glp1r−/− mice. As pharmacological inhibition of brain GLP-1R signaling impairs glucose tolerance (27), we sought complementary evidence that the brain GLP-1R system was not functional in Pdx1-hGLP1R:Glp1r−/− mice. Accordingly, we assessed the effect of i.c.v. administration of the GLP-1R antagonist exendin(9–39) (Ex-9) on glucose tolerance. Consistent with previous findings (27), i.c.v. Ex-9 impaired glucose tolerance in WT (Figure 9A) and Pdx1-hGLP1R mice (Figure 9B). However, i.c.v. Ex-9 had no effect on glucose tolerance in Glp1r−/− mice (Figure 9C) or in Pdx1-hGLP1R:Glp1r−/− mice (Figure 9D). Taken together, these findings demonstrate absence of GLP-1R signaling in CNS neurons functionally coupled to regulation of glucose homeostasis in Pdx1-hGLP1R:Glp1r−/− mice. Intriguingly, the ability of peripheral Ex-9 to impair i.p. glucose tolerance in WT and Pdx1-hGLP1R mice (Figure...
10, A and B) was absent not only in Glp1r−/− mice (Figure 10C) but also in Pdx1-hGLP1R:Glp1r−/− mice (Figure 10D). These unexpected findings imply that the actions of Ex-9 to impair glucose tolerance are dependent in part on central GLP-1R signaling.

Pharmacological activation of the β cell GLP-1R promotes expansion of β cell mass but does not increase pancreatic weight. In young rodents for which the capacity for cellular growth and proliferation is relatively high, GLP-1R agonists stimulate β cell proliferation and promote expansion of β cell mass (39, 40). To assess whether GLP-1R–dependent expansion of β cell mass represents a direct effect mediated by the islet GLP-1R, we treated 8- to 12-week-old high-fat fed mice with Ex-4 for 10 days. Ex-4 produced a significant increase in β cell mass (Figure 11A) and proliferation (Figure 11, B and C) in Pdx1-hGLP1R:Glp1r−/− mice. In WT and Pdx1-hGLP1R mice, this identical treatment regimen did not affect β cell mass (Figure 11A) or proliferation (Figure 11, B and C), likely due to the 10% reduction in body weight observed in WT and Pdx1-hGLP1R mice but not Pdx1-hGLP1R:Glp1r−/− mice after Ex-4 administration.

As GLP-1R agonists also increase the mass of the entire pancreas (18, 41) and small bowel (42), we examined whether these trophic effects were mediated indirectly through the β cell GLP-1R. Consistent with previous findings (39, 43), a 10-day course of Ex-4 administration in older mice did not increase β cell mass (Figure 12A) but significantly increased the mass of the pancreas (Figure 12B) and small bowel (Figure 12C) in WT and Pdx1-hGLP1R transgenic mice. In contrast, no significant changes in pancreatic or small bowel mass were detected in Glp1r−/− or Pdx1-hGLP1R:Glp1r−/− mice (Figure 12, B and C). Ex-4 treatment also increased levels of Irs2, Gck, and Ins2 mRNA transcripts, consistent with the predominant exocrine localization of these mRNAs in the pancreas (Figure 12, D–I). These results indicate that selective restoration of the β cell GLP-1R is not sufficient to transmit a GLP-1R–dependent growth-promoting signal to the exocrine pancreas or small bowel.

Discussion

The incretin concept describes the potentiation of glucose-stimulated insulin secretion after enteral glucose ingestion by gut-derived factors, predominantly GIP and GLP-1. Nevertheless, the widespread distribution of GLP-1R expression in extrapancreatic sites, such as the brain and peripheral nerves (29, 44, 45), illustrates that the glucoregulatory actions of GLP-1 are complex and
involve multiple tissues beyond the β cell. Moreover, a combination of gain- and loss-of-function studies support the importance of peripheral GLP-1-regulated neural circuits as mediators of glucose homeostasis. For example, activation of GLP-1R signaling in the portal vein leads to enhanced glucose clearance without changes in levels of plasma insulin (21, 46, 47). Conversely, selective interruption of portal GLP-1R signaling using antagonists impairs glucose clearance (21, 29). Hence, the available evidence invokes a role for peripheral GLP-1R-dependent control of glucose homeostasis, independent of changes in islet hormones (48).

The observations that the proglucagon gene is expressed in the CNS (24, 49) and that proglucagon-derived peptides, including GLP-1, are widely distributed to multiple CNS neurons that also express the GLP-1R (25, 50) raised the possibility that central GLP-1R signaling controls pathways important for metabolic homeostasis. Activation of central GLP-1Rs regulates food intake (16), interoceptive stress (51), blood pressure (38), and adipocyte lipid storage (52). Moreover, CNS GLP-1Rs also control peripheral insulin sensitivity and muscle glycogen synthesis (7, 53), and central GLP-1R blockade increased glycemic excursion after i.p. glucose challenge in rats (27).

The potential glucoregulatory signals arising from GLP-1Rs in multiple tissues bring into question the relative importance of the pancreatic GLP-1R for control of glucose homeostasis. As tissuespecific disruption of the Glp1r gene in key tissues has not yet been described, we used a transgenic strategy for selective restoration of GLP-1R expression in ductal and islet cells in the pancreas of Glp1r−/− mice. The observations that food intake and gastric emptying were insensitive to exogenous GLP-1R activation provide important evidence for disruption of classical GLP-1R–dependent CNS pathways in Pdx1-hGLP1R:Glp1r−/− mice. Furthermore, the failure of peripheral Ex-4 to activate c-fos expression, coupled with the inability of i.c.v. Ex-9 to cause deterioration in glucose tolerance, further supports the functional disruption of CNS GLP-1R circuits in Pdx1-hGLP1R:Glp1r−/− mice. Hence, the available evidence supports the use of Pdx1-hGLP1R:Glp1r−/− mice as a suitable model for analysis of the importance of both endogenous and pharmacological pancreatic GLP-1R activation for control of glucose homeostasis.

Nevertheless, it is important to acknowledge certain caveats in the interpretation of data obtained using Pdx1-hGLP1R:Glp1r−/− mice. First, it is impossible to rule out a small contribution to regulation of glucose homeostasis from one or more extrapancreatic sites, despite lack of evidence supporting the existence of functional CNS GLP-1Rs. Theoretically, Glp1r−/− mice may have evolved compensatory mechanisms leading to selective downregulation of extrapancreatic glucoregulatory mechanisms, making

Figure 6
The effect of Ex-4 on gastric emptying is absent in Pdx1-hGLP1R:Glp1r−/− mice. After a 6-hour fast, male mice were injected with either vehicle (PBS) or Ex-4, 30 minutes prior to an oral gavage of glucose (1.5 g/kg) and acetaminophen (0.1 g/kg). The appearance of acetaminophen in plasma samples was used as a measure of gastric emptying in (A) WT, (B) Pdx1-hGLP1R, (C) Glp1r−/−, and (D) Pdx1-hGLP1R:Glp1r−/− mice. Differences in acetaminophen absorption were quantified by comparing the total AUC for plasma acetaminophen from 0 to 60 minutes (insets). n = 5–12. *P < 0.05 versus PBS.
these actions more difficult to detect. We did not detect significant differences in islet expression of important GLP-1R–sensitive glucose regulatory genes, such as Pdx1, Glut2, Gck, Kir6.2, Gipr, or Ins2, in Pdx1-hGLP1R:Glp1r−/− mice (Supplemental Figure 1), and the islet response to exogenous Ex-4 was comparable to that in Pdx1-hGLP1R:Glp1r−/− mice (Figures 2 and 3). Nevertheless, we cannot completely eliminate the possibility that transgenic islets might exhibit enhanced coupling to downstream signaling pathways, leading to increased GLP-1R–dependent glucoregulatory activity arising from islet transgene expression.

Given the considerable evidence supporting a role for pharmacological levels of GLP-1 in the activation of insulin secretion and glucose homeostasis (54), it is perhaps not unexpected that restoration of islet GLP-1R expression was sufficient for restoring a robust glucoregulatory and insulinotropic response to exogenous Ex-4 in Pdx1-hGLP1R:Glp1r−/− mice. Similarly, GLP-1R activation leads to β cell proliferation in rodents in vivo (55) and in islet cells ex vivo (56); hence, it seems reasonable that restoration of islet GLP-1R expression restores GLP-1R–dependent stimulation of β cell proliferation and expansion of β cell mass. In contrast, Ex-4 was unable to increase the mass of the pancreas or small bowel in Pdx1-hGLP1R:Glp1r−/− mice, demonstrating that the trophic actions of GLP-1R agonists on these tissues require input from extrapancreatic GLP-1Rs. Unexpectedly, despite restoration of islet GLP-1R expression, the antagonist Ex-9 did not impair glucose homeostasis after i.p. glucose homeostasis in Pdx1-hGLP1R:Glp1r−/− mice. More surprisingly, restoration of basal levels of GLP-1R expression in Glp1r−/− islets was sufficient to normalize glucose tolerance in Glp1r−/− mice. The preferential improvement in i.p. glucose homeostasis compared with oral glucose tolerance in Pdx1-hGLP1R:Glp1r−/− mice is consistent with failure to restore the GLP-1R–dependent control of gastric emptying and in agreement with our original findings of increased fasting glucose and abnormal i.p. glucose tolerance in Glp1r−/− mice (33). These latter findings strongly suggest that the low basal levels of endogenous GLP-1, continuously secreted in the absence of nutrient ingestion, convey a physiologically important endocrine signal to islet GLP-1Rs. Taken together, the findings in Pdx1-hGLP1R:Glp1r−/− mice provide further support for an important role for islet GLP-1R signaling in the integrated GLP-1R–dependent control of glucose homeostasis (20). It seems likely that ongoing genetic studies elucidating the importance of enhanced versus disrupted GLP-1R signaling in the central and peripheral nervous system and pancreas will further refine our understanding of the complexity of incretin action.

Methods

Animal experiments. Transgenic mice were generated by pronuclear injection of a DNA construct containing the 5′ promoter sequence (4.6 kb) of the mouse Pdx1 gene (30), the human GLP-1R cDNA (2.4 kb), and a poly-A signal (0.6 kb) into fertilized eggs. Mice that contained the Pdx1-hGLP1R transgene were backcrossed to the C57BL/6 inbred strain. Pdx1-hGLP1R transgenic mice were then crossed to Glp1r−/− mice (33) in the C57BL/6 background. To generate Pdx1-hGLP1R:Glp1r−/− mice and the littermate

Figure 7

The effect of Ex-4 on food intake is absent in Pdx1-hGLP1R:Glp1r−/− mice. Food intake in male mice, after an overnight fast, was assessed after injection of either vehicle (PBS) or Ex-4. Cumulative food intake upon refeeding was recorded at 2, 4, 8, and 24 hours in (A) WT, (B) Pdx1-hGLP1R, (C) Glp1r−/−, and (D) Pdx1-hGLP1R:Glp1r−/− mice. n = 7–11. *P < 0.05 versus PBS.
controls used for all experiments, hemizygous transgenic mice (Pdx1-hGLP1R:Glp1r+/– mice) were crossed to Glp1r+/– mice. Mice of the different genotypes were born in the expected Mendelian ratios, with approximately 1 out of every 8 mice exhibiting the Pdx1-hGLP1R:Glp1r–/– genotype. Mice were genotyped using 2 separate PCRs: one specifically detected the human GLP-1R transgene (5’-TCAAGGTCAACGGCTTATTAG-3’ and 5’-TAACGTGTCCCTAGATGAACC-3’ generating a 481-bp fragment), and the other detected the presence of either the endogenous Glp1r WT allele (5’-TACAATGAGGGAGCCCTA-3’ and 5’-AAGTCTAGGGATGTGTGTGGA-3’ generating a 437-bp fragment) or the neo-containing Glp1r knockout allele (5’-CTTGGGTGGAGAGGCTATTC-3’ and 5’-AGGTGAGATGACAGGAGATC-3’ generating a 280-bp fragment). All mice were housed under specific pathogen–free conditions in microisolator cages and maintained on a 12-hour-light cycle, with free access to food and water.

To assess the effects of chronic GLP-1R activation, older chow-fed male mice (approximately 6 months old) or young male mice (8 to 12 weeks old) fed a high-fat diet for 4 weeks (45% kcal from fat; Research Diets) were injected twice daily with 1 μg Ex-4 (California Peptide Research) for 10 days. To assess the number of proliferating β cells, 5-bromo-2’-deoxyuridine (BrdU; Sigma-Aldrich) was administered daily (50 mg/kg) over the course of the treatment period. At the end of the treatment period, mice were euthanized by CO2 inhalation, tissues were excised, and the weights of the pancreata and small intestines were recorded. Immunohistochemical (IHC) analysis of formalin-fixed pancreas sections was carried out as previously described (57). The primary antibodies used for IHC were a rabbit anti-human GLP-1R (Lifespan, LS-A1205), a guinea pig anti-insulin (Invitrogen, 18-0067), and a rat mAb to BrdU (Abcam, ab6326). The insulin- and BrdU antibody–stained sections were scanned using the Scanscope.
The effect of i.c.v Ex-9 on glucose tolerance is absent in Pdx1-hGLP1R:Glp1r–/– mice. The response to an i.p. glucose challenge (IPGTT; 1.5 g/kg of body weight) in fasted male mice was assessed 20 minutes after an i.c.v. injection of either vehicle (PBS) or Ex-9 (5 μg). Blood glucose levels in (A) WT, (B) Pdx1-hGLP1R, (C) Glp1r–/–, and (D) Pdx1-hGLP1R:Glp1r–/– mice were monitored throughout the experiment. Differences in the blood glucose excursion in response to PBS compared with that for Ex-9 were quantified by comparing the total AUC (bottom insets) for glucose from 0 to 120 minutes. Plasma insulin levels (top insets) were measured in samples collected 10 minutes after glucose administration. n = 4–7. *P < 0.05 versus PBS.
used for analysis of cAMP production. KRB was supplemented with 100 μM IBMX, and the experiment was terminated after 15 minutes by the addition of cold ethanol (at a final concentration of 65%). After sonication, total cAMP levels were measured using a cAMP RIA Kit (Biomedical Technologies). Batches of 80 islets were used to generate samples for assessing the levels of pAkt by Western blot. After 30 minutes of stimulation with glucose (16.7 mM) or glucose and Ex-4 (10 nM), islets were washed with cold PBS and resuspended in SDS sample buffer containing β-mercaptoethanol, boiled for 5 minutes, and stored at −20°C pending analysis.

For determination of glucose-stimulated insulin secretion, batches of 50 islets were placed in a perifusion chamber (capacity 1.3 ml) at 37°C and perifused at a flow rate of 1 ml/min, as described previously (61). Islets were first equilibrated for 30 minutes in KRB with 2.8 mM glucose. This was followed by perifusion with KRB containing 16.7 mM glucose for 30 minutes and followed by the addition of 10 mM GLP-1 (7–36) amide (Bachem) for a final 30 minutes. Fractions were collected at several time points, and insulin was measured using a rat insulin RIA Kit (Millipore). At the end of the experiment, islets were collected and lysed in acid ethanol for measurement of total insulin content. For each sample, the amount of insulin present was normalized to insulin content. The results from the high-glucose stimulation are presented as fold increase from basal (low glucose) conditions, and the results for the GLP-1 stimulation are presented as fold increase over high-glucose conditions.

**Western blotting.** Islet protein was separated by SDS-PAGE, transferred to nitrocellulose membranes, and blocked in either 5% BSA or 5% milk in TBS-T for 1 hour before incubation with primary antibodies overnight at 4°C. The primary antibodies for pAkt (Cell Signaling no. 9275) and Akt (Cell Signaling no. 9272) were diluted 1:1,000 in 5% BSA, and the antibody for HSP90 (BD Biosciences, no. 610418) was diluted 1:5,000 in 5% milk. Secondary antibodies were linked to horseradish peroxidase (GE Healthcare), and bands were visualized by exposure to BioMax film, (Kodak) using enhanced chemiluminescence (GE Healthcare). Densitometry was quantified using Scion Image software (Scion Corp).

**Glucose tolerance tests.** Glucose tolerance tests were carried out in 3- to 6-month-old male and female mice. After an overnight fast (16–18 hours), glucose (1.5 mg/g body weight) was administered via either an oral gavage (oral glucose tolerance test [OGTT]) or i.p. injection (IPGTT). In some experiments, Ex-4 (1 μg), Ex-9 (5 μg), or vehicle (PBS) was administered via i.p. injection 30 minutes prior to glucose administration. In a separate set of experiments, 5 μg Ex-9 or vehicle (PBS) was administered 20 min-
utes prior to glucose by i.c.v. injection, as described previously (15). Blood samples were drawn from the tail vein immediately prior to any treatment and at 0, 10, 20, 30, 60, and 120 minutes after glucose loading. Blood glucose levels were measured using a Glucometer (Bayer). For plasma insulin, glucagon, GLP-1, and GIP determinations, blood samples (50 or 100 μl) were collected from the tail vein into EDTA-coated tubes 10 minutes after glucose loading, and plasma was separated by centrifugation at 4°C and stored at −20°C until assayed as described previously (62). Plasma insulin levels were measured using a mouse insulin ELISA Kit (Alpco) or a rat insulin RIA Kit (Millipore). Mice that were subject to i.c.v. injections were euthanized at the completion of the experiment. All other mice were allowed to recover for 1 week before repeating the glucose tolerance test with the alternative treatment.

Assessment of gastric emptying. In 4- to 5-month-old male mice that were fasted for 6 hours, the acetaminophen absorption test (63) was used to assess the rate of gastric emptying. Ex-4 (1 μg) or vehicle (PBS) was administered via i.p. injection 30 minutes prior to oral administration of a glucose solution that contained 1% (w/v) acetaminophen (Sigma-Aldrich). The dose of acetaminophen administered was 100 mg/kg. Tail vein blood (50 μl) was collected into EDTA-coated tubes at 0, 15, 30, and 60 minutes after acetaminophen administration. Plasma was separated by centrifugation at 4°C and stored at −20°C until measurement of acetaminophen levels using an enzymatic-spectrophotometric assay (Cambridge Life Sciences). All mice were allowed to recover for 1 week before the test was repeated with the alternative treatment.

Analysis of food intake. Mice fasted overnight (16–18 hours) were injected with either Ex-4 (1 μg) or vehicle (PBS) and then placed into individual cages containing preweighed rodent chow (Harlan Teklad no. 7012) (with free access to water). Food was weighed after 2, 4, 8, and 24 hours, and food intake was expressed as grams consumed per kilogram of body weight. All mice were allowed to recover for 1 week before the food intake measurements were repeated with the alternative treatment.

Assessment of c-FOS expression in the hindbrain. The number of c-FOS-immunoreactive neurons in specific brain regions after Ex-4 administration was assessed as described previously (64). Briefly mice were fasted for 3 hours prior to i.p. injection of either Ex-4 (10 nmol/kg) or vehicle (PBS). After

---

**Figure 11**
Ex-4 increases β cell mass and proliferation in Pdx1-hGLP1R:Glp1r−/− mice. After 10 days of Ex-4 (twice daily) or vehicle (PBS) injections (A) β cell mass and (B) the number of BrdU-positive islet cells were assessed via IHC analysis of pancreas sections from high-fat fed WT, Pdx1-hGLP1R, Glp1r−/−, and Pdx1-hGLP1R:Glp1r−/− mice. n = 3–6. *P < 0.05 versus PBS. (C) Representative images of islets stained for insulin and BrdU. Original magnification, ×20.
60 minutes, mice were deeply anesthetized with avertin and transcardially perfused with ice-cold 4% paraformaldehyde. Whole brains were removed, post-fixed in 4% paraformaldehyde at 4°C for 24 hours, and then transferred to 10% sucrose solution before being frozen. Brains were stored at –80°C until 100-μm sections of the hindbrain were cut using a vibratome. Sections were processed for immunocytochemical detection of c-FOS using a conventional avidin-biotin-immunoperoxidase method (Standard Elite Vectastain ABC Kit, Vector Laboratories). The anti-FOS antibody (Santa Cruz Biotechnology Inc., no. sc-52) was used at a dilution of 1:1,000. Brain sections corresponding to the level of the AP and the NTS were defined according to a mouse brain atlas (65). Using the Scion Image analysis software, the margins of the AP and NTS were defined using a dashed outline, and the number of FOS-positive neurons in that area were counted.

To assess c-fos mRNA levels in specific brain regions, Ex-4 (4 nmol/kg) was administered via i.p. injection 45 minutes prior to the dissection of the hindbrain. After decapitation, whole brains were rapidly removed and placed on a chilled stainless steel plate. A coronal cut was made just posterior of the obex, and another cut was made 1 mm anterior to this cut. The resulting section was placed on the stainless steel plate and the AP and NTS were dissected under magnification. RNA was extracted from these samples, and c-fos mRNA transcript levels were assessed using a Taqman Real-Time PCR gene expression assay (Applied Biosystems), with Ppia used as the internal control gene.

Statistics. All data are presented as mean ± SEM. The Prism software package (version 4; GraphPad) was used to complete the statistical analysis. Paired, 1-tailed t tests or 2-way ANOVA (with Bonferroni post-hoc analysis) were used to assess the differences in glucose tolerance, gastric emptying, and food intake data, where measurements were repeated on the same mice with each treatment. For all other data, unpaired, 1-tailed t tests or 1-way ANOVA (with Dunnett’s multiple comparison test) were used to analyze differences among the control group and one or more independent treatment groups. A P value of less than 0.05 was considered significant.

Figure 12
Effects of 10-day Ex-4 treatment (twice daily) on (A) β cell mass, (B) pancreatic weight, (C) small bowel weight, and (D–I) pancreatic gene expression in 6-month-old Pdx1-hGLP1R:Glp1r–/– and control mice. (D–F) The relative levels of genes involved in normal β cell function and (G–I) genes associated with the exocrine pancreas were quantified by real-time PCR analysis. n = 6–14. *P < 0.05 versus PBS.
D.J. Drucker is supported in part by a Canada Research Chair in Regulory Peptides and a Banting and Best Diabetes Centre Novo Nordisk Chair in Incretin Biology. These studies were supported in part by CIHR operating grants MOP 82700 and the Merck Frost Training Program in Incretin Biology (to D.J. Drucker) and MOP 86544 (to H.Y. Gaisano).

Received for publication September 2, 2011, and accepted in revised form November 2, 2011.

Address correspondence to: Daniel J. Drucker, Mount Sinai Hospital, SLRI, 600 University Ave. TCP5-1004, Toronto, Ontario M5G 1X5, Canada. Phone: 416.361.2661; Fax: 416.361.2669; E-mail: d.druker@utoronto.ca.


Supplemental Figure 1. Analysis of gene expression in islets from Pdx1-hGLP1R:Glp1r-/- and control mice. Real-time PCR analysis determined the relative levels of Pdx1, Gipr, Glu2, Gck, Kir6.2, Akt1, and Ins2 gene transcripts in islets from wild-type, Pdx1-hGLP1r, Glp1r-/- and Pdx1-hGLP1R:Glp1r-/- mice. Ppia was used as an internal control gene. n=6-8
Supplemental Figure 2. Plasma hormone levels in Pdx1-hGLP1R:Glp1r-/- and control mice following oral glucose administration. Total GLP-1 (A), total GIP (B) and glucagon (C) levels were measured in plasma collected 10 min after oral glucose administration.
Supplemental Figure 3. The effect of exendin-4 (Ex-4) on oral glucose tolerance is restored in Pdx1-hGLP1R:Glp1r-/− mice. The response to an oral glucose challenge (OGTT, 1.5 g/kg of body weight) in fasted male mice was assessed 30 min after an IP injection of either vehicle (PBS) or Ex-4 (1 µg). Blood glucose levels in wildtype (A), Pdx1-hGLP1R (B), Glp1r-/− (C) and Pdx1-hGLP1R:Glp1r-/− mice (D) were monitored throughout the experiment. Plasma insulin levels (insets) were measured in samples collected 10 min after glucose administration. n=6-11, *P<0.05 vs. PBS.